Fig 2: cVacc vs. a DNA vaccine. Multiple copies of provirus per a cell make H9 (ATCC CRL8543) a proper source to generate cVacc that are further verified by ChIP-exo/ChIP-seq qualitatively and quantitatively. *cVacc can be generated from patient CD4 T-cells after clonal expansion and then tested after results of H9 cVaccs, serving as autologous vaccination. The cVacc elicited immune function can be tested in vitro via CD4 T-cell colony formation assays, ex-vivo in humanized mouse models, and/or in nonhuman primate models. Note that cVacc exerts so-called binary functions: 1) to efficiently express its own immunogens, such as ncRNA and epi-markers, and 2) trigger the p21-signalosome pathway to enforce the HIV into a new human endogenous retrovirus (HERV). Patient CD4 T-cells, after in vitro exposure to cVacc (in vitro vaccination), can be infused back to accomplish an autologous or allogeneic vaccination.

Fig 3: cVacc vs. a DNA vaccine. Multiple copies of provirus per a cell make H9 (ATCC CRL8543) a proper source to generate cVacc that are further verified by ChIP-exo/ChIP-seq qualitatively and quantitatively. *cVacc can be generated from patient CD4 T-cells after clonal expansion and then tested after results of H9 cVaccs, serving as autologous vaccination. The cVacc elicited immune function can be tested in vitro via CD4 T-cell colony formation assays, ex-vivo in humanized mouse models, and/or in nonhuman primate models. Note that cVacc exerts so-called binary functions: 1) to efficiently express its own immunogens, such as ncRNA and epi-markers, and 2) trigger the p21-signalosome pathway to enforce the HIV into a new human endogenous retrovirus (HERV). Patient CD4 T-cells, after in vitro exposure to cVacc (in vitro vaccination), can be infused back to accomplish an autologous or allogeneic vaccination.

Fig 4: cVacc vs. a DNA vaccine. Multiple copies of provirus per a cell make H9 (ATCC CRL8543) a proper source to generate cVacc that are further verified by ChIP-exo/ChIP-seq qualitatively and quantitatively. *cVacc can be generated from patient CD4 T-cells after clonal expansion and then tested after results of H9 cVaccs, serving as autologous vaccination. The cVacc elicited immune function can be tested in vitro via CD4 T-cell colony formation assays, ex-vivo in humanized mouse models, and/or in nonhuman primate models. Note that cVacc exerts so-called binary functions: 1) to efficiently express its own immunogens, such as ncRNA and epi-markers, and 2) trigger the p21-signalosome pathway to enforce the HIV into a new human endogenous retrovirus (HERV). Patient CD4 T-cells, after in vitro exposure to cVacc (in vitro vaccination), can be infused back to accomplish an autologous or allogeneic vaccination.

Fig 5: cVacc vs. a DNA vaccine. Multiple copies of provirus per a cell make H9 (ATCC CRL8543) a proper source to generate cVacc that are further verified by ChIP-exo/ChIP-seq qualitatively and quantitatively. *cVacc can be generated from patient CD4 T-cells after clonal expansion and then tested after results of H9 cVaccs, serving as autologous vaccination. The cVacc elicited immune function can be tested in vitro via CD4 T-cell colony formation assays, ex-vivo in humanized mouse models, and/or in nonhuman primate models. Note that cVacc exerts so-called binary functions: 1) to efficiently express its own immunogens, such as ncRNA and epi-markers, and 2) trigger the p21-signalosome pathway to enforce the HIV into a new human endogenous retrovirus (HERV). Patient CD4 T-cells, after in vitro exposure to cVacc (in vitro vaccination), can be infused back to accomplish an autologous or allogeneic vaccination.